Biotech developing a novel antibiotic for multidrug-resistant UTIs.
| Date | Round | Amount |
|---|---|---|
| Nov 2024 | Series A TXN Systems closed a $2.4M Series A from GU Ventures and angels to advance its EbsArgent antibiotic toward Phase I trials. | $2.4M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.